{"filing":{"accession_number":"0001193125-26-342336","cik":"0001177648","ticker":"ENTA","company_name":"ENANTA PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"enta-20260810.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/enta-20260810.htm"},"events":[{"id":26524,"run_id":24110,"accession_number":"0001193125-26-342336","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release for Enanta Pharmaceuticals' fiscal third quarter ended June 30, 2026. The Item 2.02 disclosure explicitly states \"Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter ended June 30, 2026,\" with the full press release furnished as Exhibit 99.1. The exhibit contains detailed financial results including revenue ($14.4 million), operating expenses, net loss ($19.5 million), and cash position ($211.5 million), along with operational updates on clinical programs. This is a standard quarterly earnings announcement material to investors.","company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27678,"accession_number":"0001193125-26-342336","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Enanta Pharmaceuticals' fiscal third quarter ended June 30, 2026. The Item 2.02 disclosure explicitly states \"Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter ended June 30, 2026,\" with the full press release furnished as Exhibit 99.1. The exhibit contains detailed financial results including revenue ($14.4 million), operating expenses, net loss ($19.5 million), and cash position ($211.5 million), along with operational updates on clinical programs. This is a standard quarterly earnings announcement material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:08:54.572703+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27678,"accession_number":"0001193125-26-342336","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Enanta Pharmaceuticals' fiscal third quarter ended June 30, 2026. The Item 2.02 disclosure explicitly states \"Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter ended June 30, 2026,\" with the full press release furnished as Exhibit 99.1. The exhibit contains detailed financial results including revenue ($14.4 million), operating expenses, net loss ($19.5 million), and cash position ($211.5 million), along with operational updates on clinical programs. This is a standard quarterly earnings announcement material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:08:54.572703+00:00","company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","filing_date":"2026-08-10"}]}